MOA Resources
Reimagining Medicine for Patients With GI Cancers
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
MOA is based on in vitro/in vivo data. Clinical benefit is unknown.
Explore Clinical Trials
Explore Clinical Trials
1L mPDAC
daNIS-1
Phase II Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in 1L mPDAC
1L mPDAC
daNIS-2
Phase III Study of NIS793 in Combination With SOC Chemotherapy in 1L mPDAC
2L mCRC
daNIS-3
Phase II Study of NIS793 and Other Novel Investigational Combinations with SOC Anti-cancer Therapy for 2L Treatments of mCRC
mCRC, mGEC, mRCC
NCT03798626
Phase 1b Study of Gevokizumab in Combination with SOC Anti-Cancer Therapies in Patients with mCRC, mGEC, and mRCC
1L Gastric
RATIONALE 305
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
Explore Compounds
Explore Compounds
NIS793
TGFβ-targeting monoclonal antibody
Spartalizumab (PDR001)
PD-1–targeting monoclonal antibody
TNO155
Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2) inhibitor
